Abiopharma

Exousia Pro, Inc. (EXO) Is a joint venture with the Japanese biotech company Progenicyte Japan Co., ltd. (PJC) to manufacture and deliver mammalian and plant-based exosomes containing nucleic acids, such as DNA and mRNA to tissues and cells. EXO has an exclusive worldwide license of this patent pending technology, and its goal is to become a leader in the manufacture and delivery of mammalian and plant based therapeutic exosomes. Under the license agreement and filed patents, EXO will be the only company capable of producing and providing loaded exosomes. EXO has developed proprietary technology that allows custom production of exosomes with enhanced genetic function that can target certain cells, tissues or organs. The company can modify the exosomes to contain the desired payload of molecules to perform needed healing functions within diseased or cancerous cells or tissues. The mission of the company is to provide genetically contained exosomes in unserved global healthcare needs such as cancer and cardiovascular diseases. The manipulation of genes at a cellular level holds the key to attacking incurable diseases such as cancer and to treat diseases that do not respond to current drug therapy. The main problem confronting pharmaceutical companies lies in the ability to deliver effective targeted genetic therapy to tissues and cells. EXOs patent pending technology has the potential answer.

Additional info from OTC:
Exousia Pro, Inc. (EXO) Is a joint venture with the Japanese biotech company Progenicyte Japan Co., ltd. (PJC) to manufacture and deliver mammalian and plant-based exosomes containing nucleic acids, such as DNA and mRNA to tissues and cells. EXO has an exclusive worldwide license of this patent pending technology, and its goal is to become a leader in the manufacture and delivery of mammalian and plant based therapeutic exosomes. Under the license agreement and filed patents, EXO will be the only company capable of producing and providing loaded exosomes. EXO has developed proprietary technology that allows custom production of exosomes with enhanced genetic function that can target certain cells, tissues or organs. The company can modify the exosomes to contain the desired payload of molecules to perform needed healing functions within diseased or cancerous cells or tissues. The mission of the company is to provide genetically contained exosomes in unserved global healthcare needs such as cancer and cardiovascular diseases. The manipulation of genes at a cellular level holds the key to attacking incurable diseases such as cancer and to treat diseases that do not respond to current drug therapy. The main problem confronting pharmaceutical companies lies in the ability to deliver effective targeted genetic therapy to tissues and cells. EXOs patent pending technology has the potential answer.